The ongoing development in new genotyping methods necessitates an
understanding of their potential benefits and limits in terms of pharmacogenomics
utility. We give an overview of technologies that can be used in pharmacogenomics
research and clinical practice in this chapter. The Human Genome Project’s completion
has paved the way for the development of clinical instruments for patient evaluation.
Pharmacogenomics may enable the identification of patients who are most likely to
benefit from a specific drug, as well as those for whom the expense and risk are greater
than the advantages. Both drug therapy’s safety and efficacy may improve. In the
future, genotyping may be used to tailor drug treatment for large groups of individuals,
lowering drug treatment costs and improving therapeutic efficacy and overall health.
Keywords: Clinical Pharmacogenetics Implementation Consortium (CPIC), Dutch Pharmacogenetics Working Group (DPWG, Pharmacogenomics (PGx), PharmGKB, US Food and Drug Administration (FDA).